Notes
myocardial infarction (MI), ischaemic stroke, hospitalisation for unstable angina pectoris, or cardiovascular death
2018 US dollars
Reference
Bhatt DL, et al. Cost-Effectiveness of Alirocumab Based on Evidence From a Large Multinational Outcome Trial: The ODYSSEY OUTCOMES Economics Study. Internet Document : 10 Nov 2018. Available from: URL: https://professional.heart.org/professional/EducationMeetings/MeetingsLiveCME/ScientificSessions/UCM_502963_Science-News-2018-Late-Breaking-Science-Scientific-Sessions.jsp#odyssey-cost
Rights and permissions
About this article
Cite this article
ODYSSEY OUTCOMES: alirocumab cost effective after ACS. PharmacoEcon Outcomes News 816, 22 (2018). https://doi.org/10.1007/s40274-018-5442-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-018-5442-9